ABSTRACT
A unique method for creating drug-related nanofibers (NFs) involves electrospinning. According to reported procedures, therapies utilizing hazardous solvents or synthetic chemicals have not been authorized by the most recent drug regulations. This chapter has concentrated on studies that meet the criteria for non-toxic substances. In order to provide ideal circumstances for generating NF, electrospinning, its benefits, solutions, and process conditions, followed by characterization, will focus on safety and a regulatory emphasis. The current state of characterization of NFs is being reviewed, especially regarding chemicals entrapped within them. This makes the electrospinning application of drug-loaded NFs composition-dependent; so far, much research has been carried out using toxic solvents and FDA-unapproved crosslinking systems. The parameters of processing provide a way for the technology to be potentially accepted in the pharmaceutical industry. It has been concluded that suggestions concerning reproducibility, repeatability, and erroneous conclusions arise from the poor understanding of NF characterization techniques. Static NF release models were created that can provide safety evidence. However, some dynamic models for release can give better limitations regarding nontoxic nanostructured matrices. Many countries have developed, or at least are in the process of developing, standards. Finally, issues related to new biopolymers, their applications, and trends that can facilitate the commercialization of drug-related NFs were addressed.
